<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03757429</url>
  </required_header>
  <id_info>
    <org_study_id>2017-515IMAR</org_study_id>
    <nct_id>NCT03757429</nct_id>
  </id_info>
  <brief_title>Inflammatory Mediators Associated With Infection by Respiratory Syncytial Virus</brief_title>
  <acronym>IMAR</acronym>
  <official_title>Inflammatory Mediators Associated With Infection by Respiratory Syncytial Virus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Uppsala University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Swedish University of Agricultural Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Uppsala University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Infection with human respiratory syncytial (RS) virus is the most common cause of hospital
      stay due to pediatric lower respiratory tract infection. An exaggerated immune response
      contributes to the pathogenesis and small children may have over reactive airways for a long
      time after an infection.

      New research has shown that polymorphonuclear leukocytes (PMNs) are stimulated by the virus.
      Besides fighting the infection they also cause collateral damage to the host. Among other
      mechanisms PMNs stimulates mucus formation that affects breathing. They also secrete enzymes,
      toxic proteins and free radicals that may cause harm to lung tissue and airways.

      The current project strives towards identifying and quantifying inflammatory mediators in
      sputum, urine and blood of children with severe RS-virus infection. The ultimate aim of the
      project is to, in detail, describe proteins contributing to the pathogenesis of the disease.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2018</start_date>
  <completion_date type="Anticipated">January 2022</completion_date>
  <primary_completion_date type="Anticipated">May 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Levels of inflammatory mediators in sputum</measure>
    <time_frame>Up to three weeks</time_frame>
    <description>Simultaneous detection and quantification of hundreds of potential mediators using mass-spectrometry</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Levels of inflammatory mediators in blood</measure>
    <time_frame>Up to three weeks</time_frame>
    <description>Simultaneous detection and quantification of hundreds of potential mediators using mass-spectrometry</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Levels of inflammatory mediators in urine</measure>
    <time_frame>Up to three weeks</time_frame>
    <description>Simultaneous detection and quantification of hundreds of potential mediators using mass-spectrometry</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease severity as measured by sequential organ failure assessment score (SOFA-score)</measure>
    <time_frame>Up to 30-days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lung function as measured in respirator</measure>
    <time_frame>Up to 30-days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lung function as measured by spirometry</measure>
    <time_frame>Within 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lung function as measured by spirometry</measure>
    <time_frame>Within 10 years</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Respiratory Tract Infections</condition>
  <condition>Respiratory Syncytial Virus Infections</condition>
  <arm_group>
    <arm_group_label>RS-virus infection with mechanical ventilation</arm_group_label>
    <description>Patients admitted to the pediatric ICU with verified or suspected RS-virus infection that are mechanically ventilated.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-RS-virus infection with mechanical ventilation</arm_group_label>
    <description>Patients admitted to the pediatric ICU due to a cause other than a verified or suspected respiratory tract infection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>RS-virus infection</intervention_name>
    <description>The intervention consists of lower respiratory tract infection due to RS-virus</description>
    <arm_group_label>Non-RS-virus infection with mechanical ventilation</arm_group_label>
    <arm_group_label>RS-virus infection with mechanical ventilation</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Children admitted to pediatric ICU
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Admission to pediatric intensive care unit

          -  Clinical need for invasive ventilation

          -  Clinical need for intravascular catheterization

          -  Clinical need for urine bladder catheterization

          -  Patients with verified or suspected RS-virus-infection or no respiratory tract
             infection (control group)

        Exclusion Criteria:

        • Chronic inflammatory lung disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Akademiska sjukhuset, Centraloperation</name>
      <address>
        <city>Uppsala</city>
        <zip>75185</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Frithiof, MD PhD</last_name>
      <phone>0736563473</phone>
      <email>robert.frithiof@surgsci.uu.se</email>
    </contact>
    <contact_backup>
      <last_name>Henrik Reinius, MD, PhD</last_name>
      <email>henrik.olivero.reinius@akademiska.se</email>
    </contact_backup>
    <investigator>
      <last_name>Jean-Francois Valarcher, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sara Hägglund, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>November 22, 2018</study_first_submitted>
  <study_first_submitted_qc>November 27, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 29, 2018</study_first_posted>
  <last_update_submitted>November 27, 2018</last_update_submitted>
  <last_update_submitted_qc>November 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Uppsala University</investigator_affiliation>
    <investigator_full_name>Robert Frithiof</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Respiratory Tract Infections</mesh_term>
    <mesh_term>Respiratory Syncytial Virus Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

